Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility

Lancet. 2003 Jan 11;361(9352):182-3; author reply 183-4. doi: 10.1016/S0140-6736(03)12222-2.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Deferiprone
  • Deferoxamine / therapeutic use*
  • Heart / drug effects*
  • Humans
  • Iron Chelating Agents / therapeutic use*
  • Liver / drug effects*
  • Liver / metabolism
  • Pyridones / therapeutic use*
  • beta-Thalassemia / drug therapy*

Substances

  • Iron Chelating Agents
  • Pyridones
  • Deferiprone
  • Deferoxamine